Gain Therapeutics to Participate at the H.C. Wainwright Bioconnect Virtual Conference

Rhea-AI Summary

Gain Therapeutics, Inc. (Nasdaq: GANX) announced CEO Eric Richman will participate in the H.C. Wainwright BioConnect Conference from January 10-13, 2022. This virtual event will enable investor access via webcast, available for 90 days post-event. Gain Therapeutics focuses on innovative drug discovery, particularly targeting allosteric binding sites related to neurodegenerative diseases and lysosomal storage disorders. Supported by notable foundations and programs, the company aims to provide new treatment options for challenging disorders linked to protein misfolding.

BETHESDA, Md., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on identifying and optimizing allosteric binding sites that have never been targeted in neurodegenerative diseases and lysosomal storage disorders, today announced that Chief Executive Officer Eric Richman, will participate in the H.C. Wainwright Bioconnect Conference and invites investors to participate via webcast. Please see additional details below:

H.C. Wainwright  BioConnect Virtual Conference

Monday, January 10th - Wednesday, January 13th Registration Link A webcast will be available for 90 days on the Investor Relations section of the Gain Therapeutics website on January 10th at 7am ET or by using the following link: Webcast Link

About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is positioned at the confluence of technology and healthcare and focused on redefining drug discovery with its SEE-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding. Gain was established in 2017 with the support of its founders and institutional investors. It has been awarded funding support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse. In July 2020, Gain Therapeutics, Inc. completed a share exchange with Gain Therapeutics, SA, a Swiss corporation, whereby GT Gain Therapeutics SA became a wholly owned subsidiary of Gain Therapeutics, Inc.

For more information, visit https://www.gaintherapeutics.com/

Investor Contact:
Daniel Ferry
LifeSci Advisors
+1 617-430-7576
daniel@lifesciadvisors.com

FAQ

When will the H.C. Wainwright BioConnect Conference take place for Gain Therapeutics (GANX)?

The conference will occur from January 10 to January 13, 2022.

How can investors access the Gain Therapeutics (GANX) conference webcast?

Investors can access the webcast through the Gain Therapeutics Investor Relations section starting January 10, 2022, at 7 AM ET.

What is the focus of Gain Therapeutics (GANX)?

Gain Therapeutics focuses on identifying and optimizing allosteric binding sites for neurodegenerative diseases and lysosomal storage disorders.

What innovative platform does Gain Therapeutics (GANX) use for drug discovery?

Gain Therapeutics utilizes the SEE-Tx™ target identification platform to redefine drug discovery.

How long will the webcast for Gain Therapeutics (GANX) be available?

The webcast will be available for 90 days after the event concludes.